GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients
- 30 November 2015
- journal article
- Published by Springer Nature in Neurological Sciences
- Vol. 37 (3) , 361-364
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Deferiprone in Friedreich ataxia: A 6‐Month randomized controlled trialAnnals of Neurology, 2014
- Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation studyThe Lancet, 2014
- Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxiaMovement Disorders, 2014
- Erythropoietin in Friedreich ataxiaJournal of Neurochemistry, 2013
- Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia modelHuman Molecular Genetics, 2012
- Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severityMovement Disorders, 2011
- Friedreich's ataxia: Pathology, pathogenesis, and molecular geneticsJournal of the Neurological Sciences, 2011
- Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialThe Lancet, 2009
- IFN-γ: Recent Advances in Understanding Regulation of Expression, Biological Functions, and Clinical Applications2007
- Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scaleNeurology, 2005